Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nightingale HealthNGHLF 67 3-Year EBITDA Growth Rate is 3.50% as of Dec. 2025. GuruFocus rates NGHLF with a GF Score™ of 67/100 and a GF Value™ of $4.22. The stock has 6 warning signs investors should review. Among 526 Healthcare Providers & Services companies, Nightingale Health ranks worse than 64.07% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -13.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nightingale Health was 3.50% per year. The lowest was -32.60% per year. And the median was -18.20% per year.
Nightingale Health (OTCPK:NGHLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Nightingale Health 3-Year EBITDA Growth Rate Related Terms
NGHLF vs VEEV, BTSG, HQY: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Nightingale Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nightingale Health 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nightingale Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Nightingale Health's 3-Year EBITDA Growth Rate falls into.
Nightingale Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.50% mean?
Nightingale Health (NGHLF) has a 3-Year EBITDA Growth Rate of 3.50% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nightingale Health and its competitors. According to the industry distribution chart, Nightingale Health ranks #337 out of 526 companies in the Healthcare Providers & Services industry, placing it in the top 64.1%.
Is Nightingale Health's 3-Year EBITDA Growth Rate too high?
Nightingale Health's current 3-Year EBITDA Growth Rate is 3.50%. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.05. Nightingale Health's value of 3.50% is 65.2% below this industry median. Based on the distribution chart, Nightingale Health ranks #337 out of 526 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Nightingale Health has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Nightingale Health's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Nightingale Health ranks #337 out of 526 companies for 3-Year EBITDA Growth Rate. This places Nightingale Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.05. Nightingale Health's value of 3.50% is 65.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.05, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nightingale Health's current 3-Year EBITDA Growth Rate of 3.50% is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Nightingale Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nightingale Health's current 3-Year EBITDA Growth Rate is 3.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nightingale Health stock overvalued right now?
Nightingale Health (NGHLF) has a current 3-Year EBITDA Growth Rate of 3.50%. The stock's GF Value™ is $4.22, compared to a current price of $1.19 — trading 71.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.50% and 65.2% below the Healthcare Providers & Services industry median of 10.05. Nightingale Health's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Nightingale Health (NGHLF), the current 3-Year EBITDA Growth Rate is 3.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nightingale Health (NGHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Nightingale Health stock appears to be undervalued.
The current stock price of $1.19 is trading 71.8% below its estimated GF Value™ of $4.22.
Key valuation signals for NGHLF:
3-Year EBITDA Growth Rate: 3.50%
GF Value™: $4.22 vs. price of $1.19 (71.8% below fair value)
Industry Position: 65.2% below the Healthcare Providers & Services median (#337 of 526)
No single metric tells the full story. See the NGHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nightingale Health PLC offers a health data platform that detects disease risks. The Health Data Platform empowers individuals to take actions to prevent diseases by allowing them access to disease risk information. With its Health Data Platform, the company connects the services of healthcare actors with the preventative health needs of individuals. The company operates in Finland, Japan, the United Kingdom, Singapore, and the USA.
67GF Score
Get the complete analysis for NGHLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGHLF has been successfully added to your 
